MECT1-MAML2 fusion transcript defines a favorable subset of mucoepidermoid carcinoma

Mitsukuni Okabe, Satoru Miyabe, Hitoshi Nagatsuka, Akihiro Terada, Nobuhiro Hanai, Motoo Yokoi, Kazuo Shimozato, Tadaaki Eimoto, Shigeo Nakamura, Noriyuki Nagai, Yasuhisa Hasegawa, Hiroshi Inagaki

Research output: Contribution to journalArticle

146 Citations (Scopus)

Abstract

Purpose: Mucoepidermoid carcinoma is the most common primary malignancy of the salivary gland. Mucoepidermoid carcinoma translocated gene 1-mastermind-like gene family (MECT1-MAML2) gene fusion was identified from a recurring t(11;19)(q21;p13) translocation, which is often the sole cytogenetic alteration in this disease. This fusion transcript has been frequently detected in nnucoepidermoid carcinoma and shown to be involved in the transformation of epithelial cells. However, its clinicopathologic significance remains unclear. Experimental Design: Seventy-one cases of mucoepidermoid carcinoma and 51 cases of nonmucoepidermoid carcinoma salivary gland tumors (including 26 Warthin tumor cases) were retrospectively analyzed. RNA was extracted from archival materials: histologic paraffin specimens in all cases and cytologic specimens in 10 mucoepidermoid carcinoma cases. The MECT1-MAML2 fusion transcript was detected by a reverse transcription-PCR assay, which can be applied to both histologic and cytologic specimens. The presence of the fusion transcript was correlated with relevant clinicopathologic and survival data of the mucoepidermoid carcinoma patients. Results: The MECT1-MAML2 fusion transcript was detected in 27 of the 71 (38%) mucoepidermoid carcinoma cases but not in any case of nonmucoepidermoid carcinoma tumors. The reverse transcription-PCR results showed no difference between histologic and cytologic specimens. Detection of the MECT1-MAML2 fusion transcript was associated with a less advanced clinical stage and a low-grade tumor histology. The presence of the transcript was associated with longer disease-free and overall survivals on univariate analysis and emerged as an independent prognostic factor for longer overall survival on multivariate analysis. Conclusions: The MECT1-MAML2 fusion transcript may be specific to mucoepidermoid carcinoma and associated with a distinct mucoepidermoid carcinoma subset that exhibits favorable clinicopathologic features and an indolent clinical course.

Original languageEnglish
Pages (from-to)3902-3907
Number of pages6
JournalClinical Cancer Research
Volume12
Issue number13
DOIs
Publication statusPublished - Jul 1 2006

Fingerprint

Mucoepidermoid Carcinoma
Carcinoma
Reverse Transcription
Adenolymphoma
Neoplasms
Polymerase Chain Reaction
Glandular and Epithelial Neoplasms
Survival
Gene Fusion
Salivary Glands
Cytogenetics
Paraffin
Genes
Disease-Free Survival
Histology
Research Design
Multivariate Analysis
Epithelial Cells
RNA

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

MECT1-MAML2 fusion transcript defines a favorable subset of mucoepidermoid carcinoma. / Okabe, Mitsukuni; Miyabe, Satoru; Nagatsuka, Hitoshi; Terada, Akihiro; Hanai, Nobuhiro; Yokoi, Motoo; Shimozato, Kazuo; Eimoto, Tadaaki; Nakamura, Shigeo; Nagai, Noriyuki; Hasegawa, Yasuhisa; Inagaki, Hiroshi.

In: Clinical Cancer Research, Vol. 12, No. 13, 01.07.2006, p. 3902-3907.

Research output: Contribution to journalArticle

Okabe, M, Miyabe, S, Nagatsuka, H, Terada, A, Hanai, N, Yokoi, M, Shimozato, K, Eimoto, T, Nakamura, S, Nagai, N, Hasegawa, Y & Inagaki, H 2006, 'MECT1-MAML2 fusion transcript defines a favorable subset of mucoepidermoid carcinoma', Clinical Cancer Research, vol. 12, no. 13, pp. 3902-3907. https://doi.org/10.1158/1078-0432.CCR-05-2376
Okabe, Mitsukuni ; Miyabe, Satoru ; Nagatsuka, Hitoshi ; Terada, Akihiro ; Hanai, Nobuhiro ; Yokoi, Motoo ; Shimozato, Kazuo ; Eimoto, Tadaaki ; Nakamura, Shigeo ; Nagai, Noriyuki ; Hasegawa, Yasuhisa ; Inagaki, Hiroshi. / MECT1-MAML2 fusion transcript defines a favorable subset of mucoepidermoid carcinoma. In: Clinical Cancer Research. 2006 ; Vol. 12, No. 13. pp. 3902-3907.
@article{6172b5645d6d4a729f1a23a95f055edb,
title = "MECT1-MAML2 fusion transcript defines a favorable subset of mucoepidermoid carcinoma",
abstract = "Purpose: Mucoepidermoid carcinoma is the most common primary malignancy of the salivary gland. Mucoepidermoid carcinoma translocated gene 1-mastermind-like gene family (MECT1-MAML2) gene fusion was identified from a recurring t(11;19)(q21;p13) translocation, which is often the sole cytogenetic alteration in this disease. This fusion transcript has been frequently detected in nnucoepidermoid carcinoma and shown to be involved in the transformation of epithelial cells. However, its clinicopathologic significance remains unclear. Experimental Design: Seventy-one cases of mucoepidermoid carcinoma and 51 cases of nonmucoepidermoid carcinoma salivary gland tumors (including 26 Warthin tumor cases) were retrospectively analyzed. RNA was extracted from archival materials: histologic paraffin specimens in all cases and cytologic specimens in 10 mucoepidermoid carcinoma cases. The MECT1-MAML2 fusion transcript was detected by a reverse transcription-PCR assay, which can be applied to both histologic and cytologic specimens. The presence of the fusion transcript was correlated with relevant clinicopathologic and survival data of the mucoepidermoid carcinoma patients. Results: The MECT1-MAML2 fusion transcript was detected in 27 of the 71 (38{\%}) mucoepidermoid carcinoma cases but not in any case of nonmucoepidermoid carcinoma tumors. The reverse transcription-PCR results showed no difference between histologic and cytologic specimens. Detection of the MECT1-MAML2 fusion transcript was associated with a less advanced clinical stage and a low-grade tumor histology. The presence of the transcript was associated with longer disease-free and overall survivals on univariate analysis and emerged as an independent prognostic factor for longer overall survival on multivariate analysis. Conclusions: The MECT1-MAML2 fusion transcript may be specific to mucoepidermoid carcinoma and associated with a distinct mucoepidermoid carcinoma subset that exhibits favorable clinicopathologic features and an indolent clinical course.",
author = "Mitsukuni Okabe and Satoru Miyabe and Hitoshi Nagatsuka and Akihiro Terada and Nobuhiro Hanai and Motoo Yokoi and Kazuo Shimozato and Tadaaki Eimoto and Shigeo Nakamura and Noriyuki Nagai and Yasuhisa Hasegawa and Hiroshi Inagaki",
year = "2006",
month = "7",
day = "1",
doi = "10.1158/1078-0432.CCR-05-2376",
language = "English",
volume = "12",
pages = "3902--3907",
journal = "Clinical Cancer Research",
issn = "1078-0432",
publisher = "American Association for Cancer Research Inc.",
number = "13",

}

TY - JOUR

T1 - MECT1-MAML2 fusion transcript defines a favorable subset of mucoepidermoid carcinoma

AU - Okabe, Mitsukuni

AU - Miyabe, Satoru

AU - Nagatsuka, Hitoshi

AU - Terada, Akihiro

AU - Hanai, Nobuhiro

AU - Yokoi, Motoo

AU - Shimozato, Kazuo

AU - Eimoto, Tadaaki

AU - Nakamura, Shigeo

AU - Nagai, Noriyuki

AU - Hasegawa, Yasuhisa

AU - Inagaki, Hiroshi

PY - 2006/7/1

Y1 - 2006/7/1

N2 - Purpose: Mucoepidermoid carcinoma is the most common primary malignancy of the salivary gland. Mucoepidermoid carcinoma translocated gene 1-mastermind-like gene family (MECT1-MAML2) gene fusion was identified from a recurring t(11;19)(q21;p13) translocation, which is often the sole cytogenetic alteration in this disease. This fusion transcript has been frequently detected in nnucoepidermoid carcinoma and shown to be involved in the transformation of epithelial cells. However, its clinicopathologic significance remains unclear. Experimental Design: Seventy-one cases of mucoepidermoid carcinoma and 51 cases of nonmucoepidermoid carcinoma salivary gland tumors (including 26 Warthin tumor cases) were retrospectively analyzed. RNA was extracted from archival materials: histologic paraffin specimens in all cases and cytologic specimens in 10 mucoepidermoid carcinoma cases. The MECT1-MAML2 fusion transcript was detected by a reverse transcription-PCR assay, which can be applied to both histologic and cytologic specimens. The presence of the fusion transcript was correlated with relevant clinicopathologic and survival data of the mucoepidermoid carcinoma patients. Results: The MECT1-MAML2 fusion transcript was detected in 27 of the 71 (38%) mucoepidermoid carcinoma cases but not in any case of nonmucoepidermoid carcinoma tumors. The reverse transcription-PCR results showed no difference between histologic and cytologic specimens. Detection of the MECT1-MAML2 fusion transcript was associated with a less advanced clinical stage and a low-grade tumor histology. The presence of the transcript was associated with longer disease-free and overall survivals on univariate analysis and emerged as an independent prognostic factor for longer overall survival on multivariate analysis. Conclusions: The MECT1-MAML2 fusion transcript may be specific to mucoepidermoid carcinoma and associated with a distinct mucoepidermoid carcinoma subset that exhibits favorable clinicopathologic features and an indolent clinical course.

AB - Purpose: Mucoepidermoid carcinoma is the most common primary malignancy of the salivary gland. Mucoepidermoid carcinoma translocated gene 1-mastermind-like gene family (MECT1-MAML2) gene fusion was identified from a recurring t(11;19)(q21;p13) translocation, which is often the sole cytogenetic alteration in this disease. This fusion transcript has been frequently detected in nnucoepidermoid carcinoma and shown to be involved in the transformation of epithelial cells. However, its clinicopathologic significance remains unclear. Experimental Design: Seventy-one cases of mucoepidermoid carcinoma and 51 cases of nonmucoepidermoid carcinoma salivary gland tumors (including 26 Warthin tumor cases) were retrospectively analyzed. RNA was extracted from archival materials: histologic paraffin specimens in all cases and cytologic specimens in 10 mucoepidermoid carcinoma cases. The MECT1-MAML2 fusion transcript was detected by a reverse transcription-PCR assay, which can be applied to both histologic and cytologic specimens. The presence of the fusion transcript was correlated with relevant clinicopathologic and survival data of the mucoepidermoid carcinoma patients. Results: The MECT1-MAML2 fusion transcript was detected in 27 of the 71 (38%) mucoepidermoid carcinoma cases but not in any case of nonmucoepidermoid carcinoma tumors. The reverse transcription-PCR results showed no difference between histologic and cytologic specimens. Detection of the MECT1-MAML2 fusion transcript was associated with a less advanced clinical stage and a low-grade tumor histology. The presence of the transcript was associated with longer disease-free and overall survivals on univariate analysis and emerged as an independent prognostic factor for longer overall survival on multivariate analysis. Conclusions: The MECT1-MAML2 fusion transcript may be specific to mucoepidermoid carcinoma and associated with a distinct mucoepidermoid carcinoma subset that exhibits favorable clinicopathologic features and an indolent clinical course.

UR - http://www.scopus.com/inward/record.url?scp=33746077108&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33746077108&partnerID=8YFLogxK

U2 - 10.1158/1078-0432.CCR-05-2376

DO - 10.1158/1078-0432.CCR-05-2376

M3 - Article

C2 - 16818685

AN - SCOPUS:33746077108

VL - 12

SP - 3902

EP - 3907

JO - Clinical Cancer Research

JF - Clinical Cancer Research

SN - 1078-0432

IS - 13

ER -